Advances in the clinical application and safety of bispecific antibodies for cancer therapy
10.6039/j.issn.1001-0408.2025.19.19
- VernacularTitle:双特异性抗体在肿瘤治疗中的临床应用及安全性研究进展
- Author:
Mengmeng LIN
1
;
Xu LIN
;
Yixuan WANG
;
Danna JIANG
;
Shanshan SHI
;
Yangling LI
Author Information
1. 西湖大学医学院附属杭州市第一人民医院药学部/浙江省临床肿瘤药理与毒理学研究重点实验室,杭州 310006
- Publication Type:Journal Article
- Keywords:
bispecific antibodies;
tumors;
anticancer drugs;
clinical application;
efficacy;
safety
- From:
China Pharmacy
2025;36(19):2466-2472
- CountryChina
- Language:Chinese
-
Abstract:
Bispecific antibodies(BsAbs),as an important recent innovation in the field of tumor immunotherapy in recent years,can simultaneously or sequentially target different antigens or two different epitopes of the same antigen.Compared with traditional monoclonal antibodies,they can produce superior therapeutic effects.This article reviews the progress in clinical applications and safety research of BsAbs in cancer therapy,revealing that they(such as blinatumomab,glofitamab,teclistamab,amivantamab,etc.)exhibit significant therapeutic efficacy against hematological malignancies,lung cancer,cervical cancer,melanoma,and other cancers.For cytokine release syndrome(CRS)induced by BsAbs,prophylactic or pre-emptive medication is commonly administered in clinical practice;for neurotoxicity and infections triggered by BsAbs,clinical practice necessitates rigorous monitoring of patients'vital signs and the provision of essential treatments.In addition,different BsAbs exhibit variations in escalation dose,infusion rate,storage duration,and equipment requirements.Therefore,strict adherence to the instructions in the drug package inserts is essential during clinical operations to ensure safety and therapeutic efficacy.In the future,more multicenter trials need to be conducted to validate the efficacy and safety of BsAbs across different tumor types and patient populations,and long-term follow-up data should be accumulated to optimize treatment cycles and dosage regimens.
